Sivolella Stefano, De Biagi Marleen, Brunello Giulia, Berengo Mario, Pengo Vittorio
Department of Neurosciences, Institute of Clinical Dentistry, University of Padova, Via Venezia 90, 35129, Padua, Italy.
DDS, Resident, Institute of Clinical Dentistry, Azienda Ospedaliera, University of Padova, Via Venezia 90, 35129, Padua, Italy.
Odontology. 2015 Sep;103(3):258-63. doi: 10.1007/s10266-015-0195-4. Epub 2015 Feb 6.
The development of new orally administered anticoagulants, such as dabigatran, rivaroxaban, and apixaban, in the past few years has focused on avoiding some of the drawbacks associated with warfarin. This work aims to illustrate the main features of the most commonly used new oral anticoagulants, reviewing the current literature on the management of patients taking these drugs and needing oral and implant surgery, and discussing the currently proposed related guidelines.
在过去几年中，新型口服抗凝剂（如达比加群、利伐沙班和阿哌沙班）的研发致力于规避与华法林相关的一些弊端。这项工作旨在阐述最常用新型口服抗凝剂的主要特点，回顾有关服用这些药物且需要进行口腔和植入手术患者管理的当前文献，并讨论目前提出的相关指南。
Zotero 插件